Axicabtagene Ciloleucel in Patients with Refractory Large B Cell Lymphoma: Outcomes by Prior Lines of Therapy in the Pivotal Phase 2 Study, ZUMA-1

被引：1

作者：

Locke, Frederick L. ^{[1
]}

Ghobadi, Armin ^{[2
]}

Lekakis, Lazaros J. ^{[3
]}

Miklos, David B. ^{[4
]}

Jacobson, Caron A. ^{[5
]}

Jacobsen, Eric ^{[5
]}

Braunschweig, Ira ^{[6
]}

Oluwole, Olalekan O. ^{[7
]}

Siddiqi, Tanya ^{[8
]}

Lin, Yi ^{[9
]}

Reagan, Patrick M. ^{[10
]}

Farooq, Umar ^{[11
]}

Deol, Abhinav ^{[12
]}

Bot, Adrian ^{[13
]}

Rossi, John M. ^{[13
]}

Jiang, Yizhou ^{[13
]}

Xue, Allen ^{[13
]}

Go, William Y. ^{[13
]}

Neelapu, Sattva S. ^{[14
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[2] Washington Univ, Sch Med, St Louis, MO USA

[3] Univ Miami Hlth Syst, Sylvester Comprehens Care Ctr, Miami, FL USA

[4] Stanford Univ, Stanford, CA 94305 USA

[5] Dana Farber Canc Inst, Boston, MA 02115 USA

[6] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA

[7] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[8] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA

[9] Mayo Clin, Rochester, MN USA

[10] Univ Rochester, Sch Med, Rochester, NY USA

[11] Univ Iowa, Iowa City, IA USA

[12] Wayne State Univ, Karmanos Canc Ctr, Detroit, MI USA

[13] Kite, Santa Monica, CA USA

[14] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2018年 / 18卷

关键词：

CAR T cell therapy; large B cell lymphoma;

D O I：

10.1016/j.clml.2018.07.203

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

NHL-102

引用

页码：S276 / S276

页数：1

共 50 条

[31] ZUMA-11: A Phase 1/2 Multicenter Study of Axicabtagene Ciloleucel (Axi-Cel) plus Utomilumab Patients with Refractory Large B Cell Lymphoma
Reshef, Ran
Miklos, David B.
Timmerman, John M.
Jacobson, Caron A.
Bennani, Nabila N.
Rossi, John M.
Sherman, Marika
Zheng, Lianqing
Sun, Jennifer
Palluconi, Gabrielle
Kim, Jenny J.
Jain, Michael D.
BLOOD, 2019, 134
[32] Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma
Koji Kato
Shinichi Makita
Hideki Goto
Junya Kanda
Nobuharu Fujii
Kazuyuki Shimada
Koichi Akashi
Koji Izutsu
Takanori Teshima
Natsuko Fukuda
Tokuhito Sumitani
Hiroyuki Sumi
Shinji Shimizu
Yasuyuki Kakurai
Kenji Yoshikawa
Kensei Tobinai
Noriko Usui
Kiyohiko Hatake
International Journal of Clinical Oncology, 2022, 27 : 213 - 223
[33] Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma
Kato, Koji
Makita, Shinichi
Goto, Hideki
Kanda, Junya
Fujii, Nobuharu
Shimada, Kazuyuki
Akashi, Koichi
Izutsu, Koji
Teshima, Takanori
Fukuda, Natsuko
Sumitani, Tokuhito
Sumi, Hiroyuki
Shimizu, Shinji
Kakurai, Yasuyuki
Yoshikawa, Kenji
Tobinai, Kensei
Usui, Noriko
Hatake, Kiyohiko
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (01) : 213 - 223
[34] Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Locke, Frederick L.
Ghobadi, Armin
Jacobson, Caron A.
Miklos, David B.
Lekakis, Lazaros J.
Oluwole, Olalekan O.
Lin, Yi
Braunschweig, Ira
Hill, Brian T.
Timmerman, John M.
Deol, Abhinav
Reagan, Patrick M.
Stiff, Patrick
Flinn, Ian W.
Farooq, Umar
Goy, Andre
McSweeney, Peter A.
Munoz, Javier
Siddiqi, Tanya
Chavez, Julio C.
Herrera, Alex F.
Bartlett, Nancy L.
Wiezorek, Jeffrey S.
Navale, Lynn
Xue, Allen
Jiang, Yizhou
Bot, Adrian
Rossi, John M.
Kim, Jenny J.
Go, William Y.
Neelapu, Sattva S.
LANCET ONCOLOGY, 2019, 20 (01): : 31 - 42
[35] A Comparison of One Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients With Refractory, Aggressive Non-Hodgkin Lymphoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (02) : 11 - 12
[36] Pretreatment immunoscore and an inflamed tumor microenvironment (TME) are associated with efficacy in patients (Pts) with refractory large B cell lymphoma treated with axicabtagene ciloleucel (Axi-Cel) in ZUMA-1
Rossi, John M.
Galon, Jerome
Chang, Edmund
Perbost, Regis
Scholler, Nathalie
Turcan, Sarah
Danan, Corinne
Locke, Frederick L.
Neelapu, Sattva S.
Miklos, David B.
Jacobson, Caron A.
Lekakis, Lazaros J.
Lin, Yi
Ghobadi, Armin
Milletti, Francesca
Go, William Y.
Bot, Adrian
CANCER RESEARCH, 2019, 79 (13)
[37] Curative Potential of Axicabtagene Ciloleucel (Axi-Cel): An Exploratory Long-Term Survival Assessment in Patients with Refractory Large B-Cell Lymphoma from ZUMA-1
Neelapu, Sattva S.
Jacobson, Caron A.
Ghobadi, Armin
Miklos, David B.
Lekakis, Lazaros J.
Spooner, Clare
Kim, Jenny J.
Miao, Harry
Xue, Allen Xiaodong
Zheng, Yan
Locke, Frederick L.
BLOOD, 2023, 142
[38] Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1.
Locke, Frederick Lundry
Bartlett, Nancy L.
Jacobson, Caron A.
Oluwole, Olalekan O.
Munoz, Javier
Lekakis, Lazaros J.
Topp, Max S.
Avivi, Irit
Kim, Jenny J.
Chu, Rong
Zheng, Lianqing
Rossi, John M.
Bot, Adrian
Neelapu, Sattva Swarup
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[39] Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy
Spiegel, Jay Y.
Dahiya, Saurabh
Jain, Michael D.
Tamaresis, John
Nastoupil, Loretta J.
Jacobs, Miriam T.
Ghobadi, Armin
Lin, Yi
Lunning, Matthew
Lekakis, Lazaros
Reagan, Patrick
Oluwole, Olalekan
McGuirk, Joseph
Deol, Abhinav
Goy, Andre
Vu, Khoan
Andreadis, Charalambos
Munoz, Javier
Bennani, N. Nora
Vose, Julie M.
Dorritie, Kathleen A.
Neelapu, Sattva S.
Locke, Frederick L.
Rapoport, Aaron P.
Hill, Brian T.
Miklos, David B.
BLOOD, 2021, 137 (13) : 1832 - 1835
[40] ZUMA-12: A Phase 2 Multicenter Study of Axicabtagene Ciloleucel as a First-Line Therapy in Patients With High-Risk Large B Cell Lymphoma
Neelapu, Sattva S.
Chavez, Julio C.
Lin, Yi
Munoz, Javier
Ujjani, Chaitra S.
Riedell, Peter
De Vos, Sven
Oluwole, Olalekan O.
Kekre, Natasha
Yang, Yin
Goyal, Lovely
Backhouse, Kate
Milletti, Francesca
Kawashima, Jun
Herrera, Alex F.
AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 : S19 - S19

← 1 2 3 4 5 →